pemafibrate
Kowa Pharmaceuticals
['cardio', 'anheart']
open access: rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (prominent) study. #aha2022 #cardiotwitter #aha22 
The American Heart Journal has been a trusted resource for cardiologists and general practice physicians for more than 80 years